Agenus (AGEN) Competitors

Agenus logo
$6.16 -0.14 (-2.15%)
As of 03:35 PM Eastern
This is a fair market value price provided by Massive. Learn more.

AGEN vs. VOR, SLN, JANX, CVAC, and MLTX

Should you buy Agenus stock or one of its competitors? Agenus's main competitors and comparable companies include Vor Biopharma (VOR), Silence Therapeutics (SLN), Janux Therapeutics (JANX), CureVac (CVAC), and MoonLake Immunotherapeutics (MLTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Agenus compare to Vor Biopharma?

Vor Biopharma (NASDAQ:VOR) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Agenus has higher revenue and earnings than Vor Biopharma.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vor BiopharmaN/AN/AN/AN/AN/A
Agenus$114.20M2.42$120K$0.669.23

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by company insiders. Comparatively, 6.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Vor Biopharma has a beta of 1.87, meaning that its share price is 87% more volatile than the broader market. Comparatively, Agenus has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

In the previous week, Vor Biopharma had 3 more articles in the media than Agenus. MarketBeat recorded 5 mentions for Vor Biopharma and 2 mentions for Agenus. Agenus' average media sentiment score of 0.91 beat Vor Biopharma's score of 0.36 indicating that Agenus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vor Biopharma
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Agenus
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vor Biopharma presently has a consensus price target of $38.29, indicating a potential upside of 107.12%. Agenus has a consensus price target of $25.00, indicating a potential upside of 310.17%. Given Agenus' higher possible upside, analysts plainly believe Agenus is more favorable than Vor Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vor Biopharma
0 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00
Agenus
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

Agenus has a net margin of 22.10% compared to Vor Biopharma's net margin of 0.00%. Vor Biopharma's return on equity of 0.00% beat Agenus' return on equity.

Company Net Margins Return on Equity Return on Assets
Vor BiopharmaN/A N/A N/A
Agenus 22.10%-27.16%26.91%

Summary

Vor Biopharma beats Agenus on 7 of the 13 factors compared between the two stocks.

How does Agenus compare to Silence Therapeutics?

Silence Therapeutics (NASDAQ:SLN) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

In the previous week, Silence Therapeutics had 4 more articles in the media than Agenus. MarketBeat recorded 6 mentions for Silence Therapeutics and 2 mentions for Agenus. Agenus' average media sentiment score of 0.91 beat Silence Therapeutics' score of 0.05 indicating that Agenus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Silence Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Agenus
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Agenus has higher revenue and earnings than Silence Therapeutics. Silence Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Silence Therapeutics$560K2,196.89-$88.61M-$1.07N/A
Agenus$114.20M2.42$120K$0.669.23

Agenus has a net margin of 22.10% compared to Silence Therapeutics' net margin of -8,943.86%. Agenus' return on equity of -27.16% beat Silence Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Silence Therapeutics-8,943.86% -102.72% -43.70%
Agenus 22.10%-27.16%26.91%

Silence Therapeutics has a beta of 1.34, suggesting that its stock price is 34% more volatile than the broader market. Comparatively, Agenus has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

98.7% of Silence Therapeutics shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Silence Therapeutics currently has a consensus target price of $24.00, suggesting a potential upside of 21.24%. Agenus has a consensus target price of $25.00, suggesting a potential upside of 310.17%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than Silence Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Silence Therapeutics
1 Sell rating(s)
4 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.14
Agenus
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Agenus beats Silence Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Agenus compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Agenus (NASDAQ:AGEN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Janux Therapeutics has a beta of 2.44, meaning that its share price is 144% more volatile than the broader market. Comparatively, Agenus has a beta of 1.53, meaning that its share price is 53% more volatile than the broader market.

Agenus has a net margin of 22.10% compared to Janux Therapeutics' net margin of 0.00%. Janux Therapeutics' return on equity of -11.80% beat Agenus' return on equity.

Company Net Margins Return on Equity Return on Assets
Janux TherapeuticsN/A -11.80% -10.97%
Agenus 22.10%-27.16%26.91%

Agenus has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Janux Therapeutics$10M65.79-$113.62M-$1.59N/A
Agenus$114.20M2.42$120K$0.669.23

In the previous week, Janux Therapeutics had 15 more articles in the media than Agenus. MarketBeat recorded 17 mentions for Janux Therapeutics and 2 mentions for Agenus. Agenus' average media sentiment score of 0.91 beat Janux Therapeutics' score of 0.36 indicating that Agenus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Janux Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
Agenus
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Janux Therapeutics currently has a consensus price target of $36.92, indicating a potential upside of 243.34%. Agenus has a consensus price target of $25.00, indicating a potential upside of 310.17%. Given Agenus' stronger consensus rating and higher possible upside, analysts clearly believe Agenus is more favorable than Janux Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics
2 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.63
Agenus
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67

75.4% of Janux Therapeutics shares are owned by institutional investors. Comparatively, 61.5% of Agenus shares are owned by institutional investors. 7.9% of Janux Therapeutics shares are owned by company insiders. Comparatively, 6.5% of Agenus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Agenus beats Janux Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Agenus compare to CureVac?

Agenus (NASDAQ:AGEN) and CureVac (NASDAQ:CVAC) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

61.5% of Agenus shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 6.5% of Agenus shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Agenus' net margin of 22.10%. CureVac's return on equity of -23.03% beat Agenus' return on equity.

Company Net Margins Return on Equity Return on Assets
Agenus22.10% -27.16% 26.91%
CureVac 199.92%-23.03%-19.09%

Agenus has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its share price is 77% more volatile than the broader market.

In the previous week, Agenus had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Agenus and 0 mentions for CureVac. Agenus' average media sentiment score of 0.91 beat CureVac's score of 0.00 indicating that Agenus is being referred to more favorably in the media.

Company Overall Sentiment
Agenus Positive
CureVac Neutral

Agenus presently has a consensus price target of $25.00, indicating a potential upside of 310.17%. Given Agenus' stronger consensus rating and higher possible upside, research analysts plainly believe Agenus is more favorable than CureVac.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
CureVac
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

CureVac has lower revenue, but higher earnings than Agenus. CureVac is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agenus$114.20M2.42$120K$0.669.23
CureVac$70.74M14.78$175.50M$0.726.47

Summary

Agenus beats CureVac on 10 of the 16 factors compared between the two stocks.

How does Agenus compare to MoonLake Immunotherapeutics?

Agenus (NASDAQ:AGEN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

61.5% of Agenus shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 6.5% of Agenus shares are owned by company insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Agenus has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agenus$114.20M2.42$120K$0.669.23
MoonLake ImmunotherapeuticsN/AN/A-$227.32M-$3.67N/A

Agenus has a net margin of 22.10% compared to MoonLake Immunotherapeutics' net margin of 0.00%. Agenus' return on equity of -27.16% beat MoonLake Immunotherapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Agenus22.10% -27.16% 26.91%
MoonLake Immunotherapeutics N/A -79.95%-56.40%

In the previous week, MoonLake Immunotherapeutics had 11 more articles in the media than Agenus. MarketBeat recorded 13 mentions for MoonLake Immunotherapeutics and 2 mentions for Agenus. Agenus' average media sentiment score of 0.91 beat MoonLake Immunotherapeutics' score of -0.09 indicating that Agenus is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agenus
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
MoonLake Immunotherapeutics
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Agenus presently has a consensus price target of $25.00, indicating a potential upside of 310.17%. MoonLake Immunotherapeutics has a consensus price target of $31.33, indicating a potential upside of 174.32%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than MoonLake Immunotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agenus
0 Sell rating(s)
2 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.67
MoonLake Immunotherapeutics
2 Sell rating(s)
2 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.60

Agenus has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.14, indicating that its stock price is 14% more volatile than the broader market.

Summary

Agenus beats MoonLake Immunotherapeutics on 11 of the 15 factors compared between the two stocks.

Get Agenus News Delivered to You Automatically

Sign up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AGEN vs. The Competition

MetricAgenusBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$277.38M$4.03B$7.73B$11.61B
Dividend YieldN/A3.62%2.46%4.43%
P/E Ratio9.2923.9734.1629.83
Price / Sales2.4416.198.475.65
Price / CashN/A26.3721.9322.50
Price / Book-2.484.064.373.65
Net Income$120K-$22.82M$3.52B$392.18M
7 Day Performance-12.32%-7.34%-5.48%-4.27%
1 Month Performance1.90%-6.15%-4.62%-6.75%
1 Year Performance42.48%-6.90%-1.57%-7.22%

Agenus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AGEN
Agenus
2.7813 of 5 stars
$6.16
-2.1%
$25.00
+306.2%
+44.9%$277.38M$114.20M9.2981
VOR
Vor Biopharma
2.1702 of 5 stars
$19.98
+0.5%
$38.29
+91.6%
+89.5%$1.24BN/AN/A76
SLN
Silence Therapeutics
2.9866 of 5 stars
$19.75
+0.1%
$24.00
+21.5%
+189.9%$1.19B$560KN/A88
JANX
Janux Therapeutics
2.7421 of 5 stars
$12.76
-27.6%
$36.92
+189.4%
-62.7%$1.11B$10MN/A113
CVAC
CureVac
N/A$4.66
flat
N/AN/A$1.05B$70.74M6.47880

Related Companies and Tools


This page (NASDAQ:AGEN) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners